检索

期
标题
作者
卷 26, 编号 1 (2024)
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L., Bolotina L., Dvornichenko V., Fadeeva N., Ganshina I., Grechukhina K., Hasanova A., Kislov N., Kudryavtsev I., Manikhas A., Musaeva N., Nizhegorodtseva A., Sadikova O., Sakaeva D., Snegovoy A., Stroyakovskiy D., Tjulandin S., Trishkina E., Vladimirova L., Volkov N., Kostalanova Y.
PDF
(Rus)
卷 25, 编号 1 (2023)
The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review
Grechukhina K., Kalugin M., Prosvirnov A., Sukhova M., Zhukova L.
PDF
(Rus)
卷 25, 编号 1 (2023)
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.
PDF
(Rus)
卷 24, 编号 2 (2022)
Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes
Snegovoy A., Kononenko I.
PDF
(Rus)
卷 25, 编号 4 (2023)
Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
Ognerubov N.
PDF
(Rus)
卷 24, 编号 3 (2022)
Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report
Grechukhina K., Vorontsova K., Filonenko D., Tyutyunnik P., Shchadrova V., Zhukova L.
PDF
(Rus)
卷 26, 编号 2 (2024)
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K., Filonenko D., Sukhova M., Zhukova L.
PDF
(Rus)
卷 20, 编号 2 (2018)
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Frolova M., Kochetkova Y., Chubenko V., Volkov N., Moiseenko F., Garmarnik T., Ponomarenko D., Orlov A., Kostalanova Y., Makarycheva Y., Nizegorodzeva A.
PDF
(Rus)
卷 23, 编号 1 (2021)
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
PDF
(Rus)
卷 20, 编号 2 (2018)
Ribociclib in 1st line HR+ breast cancer treatment
Zhukova L., Ganshina I., Gordeeva O., Lubennikova E.
PDF
(Rus)
1 - 10 的 10 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##